ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1392	National Cancer Institute	Html	en	Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version	Treatment of children with rhabdomyosarcoma often includes chemotherapy, radiation therapy, and surgery. For pediatric embryonal, alveolar, and anaplastic rhabdomyosarcoma, learn about the signs, diagnosis, prognosis, treatment regimens, and clinical trials in this expert-reviewed summary.	soft tissue 0.790585 intermediate risk rhabdomyosarcoma 0.445041 rhabdomyosarcoma cases 0.455822 childhood rhabdomyosarcoma 0.593521 rhabdomyosarcoma patients 0.545472 children 0.493211 intergroup rhabdomyosarcoma studies 0.517745 alveolar rhabdomyosarcoma patients 0.515716 rhabdomyosarcoma 0.96522 Int J Radiat 0.504093 advanced extremity rhabdomyosarcoma 0.456564 Radiat Oncol Biol 0.739922 childhood rhabdomyosarcoma incidence 0.473829 pediatric rhabdomyosarcoma patients 0.456936 patients 0.603999 spindle cell rhabdomyosarcoma 0.473635 intermediate-risk rhabdomyosarcoma 0.519136 Rhabdomyosarcoma Study-IV experience 0.444462 biliary tract rhabdomyosarcoma 0.443533 Rhabdomyosarcoma Study Group 0.470276 extremity rhabdomyosarcoma 0.461496 adult rhabdomyosarcoma patients 0.499141 soft tissue sarcoma 0.736147 et al. 0.806046 Intergroup Rhabdomyosarcoma Study 0.799018	intergroup rhabdomyosarcoma study-iv 0.552013 differentiated embryonal rhabdomyosarcoma 0.474756 PUBMED Abstract 0.447631 Pediatr Blood Cancer 0.665669 intermediate-risk rhabdomyosarcoma patients 0.477987 nonmetastatic rhabdomyosarcoma 0.468047 alveolar rhabdomyosarcoma cases 0.455418 gene-negative alveolar rhabdomyosarcoma 0.459372 typical embryonal rhabdomyosarcoma 0.456569 metastatic rhabdomyosarcoma 0.445146 group iii rhabdomyosarcoma 0.483139 Abstract 0.667848 Clin Oncol 0.743964 Intergroup Rhabdomyosarcoma Study-II 0.496765 Oncol Biol Phys 0.753212 rhabdomyosarcoma experience relapse 0.449214 tissue sarcoma committee 0.500618 orbital rhabdomyosarcoma 0.45917 alveolar rhabdomyosarcoma 0.600282 lymph node 0.533988 cell rhabdomyosarcoma patients 0.482049 intergroup rhabdomyosarcoma 0.827615 embryonal rhabdomyosarcoma 0.685831 oncology group 0.614164	CLICK HERE
1536	National Cancer Institute	Html	en	Laetrile/Amygdalin (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer.	cancer treatment 0.52441 cancer cell inhibitors. 0.542345 intravenous amygdalin treatment 0.677872 amygdalin occurs 0.621015 potential anticancer activity 0.529695 cyanide poisoning 0.73495 blood cyanide levels 0.657623 intestinal bacteria 0.607185 primordial germ cells 0.521102 purported anticancer activity 0.532782 oral amygdalin 0.650441 cancer patients 0.590892 complete responses 0.526167 high-dose vitamin supplements 0.5155 metabolic therapy 0.516142 U.S.-patented Laetrile 0.757295 laetrile therapy 0.736124 amygdalin interacts 0.616968 laetrile’s breakdown 0.71917 laetrile practitioners. 0.705315 anticancer activity 0.587095 nontoxic intravenous form 0.531127 specific anticancer properties 0.534462 intravenous Laetrile 0.740226 United States 0.629681	positive results 0.563482 case series 0.523576 cancer cells 0.637689 oral maintenance therapy 0.601513 colon cancer cells 0.550218 promising cancer therapies 0.544057 term laetrile 0.84507 human breast cancer 0.525831 laetrile treatment. 0.765844 higher-dose amygdalin therapy 0.65865 National Cancer Institute 0.610445 cyanide anion 0.594345 partial responses 0.519394 Laetrile supporters 0.777243 term vitamin B-17 0.520783 amygdalin 0.757648 enzyme beta-glucosidase 0.562945 anticancer agent 0.587895 case reports 0.550533 hydrogen cyanide 0.876372 cyanide group 0.578561 laetrile 0.994496 chemical amygdalin 0.642935 cancer 0.720035	CLICK HERE
1544	National Cancer Institute	Html	en	Adult Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.	adult aml 0.716289 red blood cells 0.594071 cancer treatment 0.467513 blood -forming cells 0.4491 acute myeloblastic leukemia 0.44585 acute myelogenous leukemia 0.445245 chemotherapy 0.473847 PDQ cancer information 0.503817 white blood cells 0.675945 clinical trials 0.938073 mature blood cells 0.50039 cancer information summary 0.459101 clinical trial 0.615294 stem cells 0.519631 stem cell transplant 0.480735 acute granulocytic leukemia 0.446114 Myeloid Leukemia Treatment 0.448761 blood cells 0.735668 radiation therapy 0.468603 treatment 0.673705 myeloid stem cell 0.438755 stored stem cells 0.437216 immature blood cells 0.448693 arsenic trioxide 0.473356	cancer cells 0.602593 specific cancer cells 0.456728 recurrent adult aml 0.474546 untreated adult aml 0.465491 acute myeloid leukemia 0.930922 stem cell 0.533281 treatment clinical trials 0.44329 blood stem cells 0.488116 National Cancer Institute 0.460343 spinal cord 0.512703 normal cells 0.467456 myeloid stem cells 0.482174 new treatment 0.480473 white blood cell 0.463646 combination chemotherapy 0.472241 bone marrow 0.747056 cells 0.827248 acute promyelocytic leukemia 0.5928 cancer clinical trials 0.452604 acute nonlymphocytic leukemia 0.445812 acute lymphoblastic leukemia 0.434651 acute leukemia 0.43925 cancer 0.808047 standard treatment 0.467846	CLICK HERE
1872	National Cancer Institute	Html	es	Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter.	Compton CC 0.310067 prognostic factors 0.311079 Roth BJ 0.353197 transitional cell carcinoma 0.558604 Sin embargo 0.332107 Ta Carcinoma 0.313126 Elson PJ 0.309122 California Oncology Group 0.314515 7th ed 0.310032 tumores renales 0.309511 pelvis renal 0.960657 Instituto Nacional 0.312591 metástasis distantes 0.32208 células transicionales recidivantes 0.361913 pared pélvica renal 0.316324 parénquima renal t3 0.317938 cooperative group study 0.316918 Cooperative Oncology Group 0.315511 tejido renal 0.313083 metastatic transitional cell 0.319135 preliminary report from 0.31524 group study 0.325781 Einhorn LH 0.327583 urinary tract 0.331593 función renal 0.325386	Northern California Oncology 0.31495 upper urinary tract 0.318654 effective chemotherapy regimen 0.317306 Oncology Group study 0.317114 Nocks BN 0.30983 Cancer Staging Manual 0.321607 PDQ Tratamiento 0.309071 Renal pelvic tumors 0.315825 New York 0.30907 Daly JJ 0.308968 with paclitaxel 0.310585 Clin Oncol 0.437926 parénquima renal 0.327814 Byrd DR 0.309554 urothelial carcinoma 0.398878 gallium combination chemotherapy 0.316792 insuficiencia renal 0.313531 Eastern Cooperative Oncology 0.315974 renal pelvis 0.422209 Oncology Group 0.324511 Tis Carcinoma 0.313191 metastatic urothelial carcinoma 0.363244 AJCC Cancer Staging 0.322547 Edge SB 0.31008	CLICK HERE
1942	National Cancer Institute	Html	es	Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica.	French-American-British Cooperative Leukaemia 0.312371 leucemia mieloide 0.341853 myelomonocytic leukaemia 0.397359 myelomonocytic leukemia with 0.326213 platelet-derived growth factor 0.354049 with juvenile chronic 0.315892 Arber DA 0.312178 health organization classification 0.3281 Leukemia Group 0.315441 genes platelet-derived growth 0.312347 with juvenile 0.340061 chronic myeloid leukemia 0.336615 myelomonocytic leukemia 0.944712 leucemia mielomonocítica 0.387953 chronic myelomonocytic leukemia 0.819447 differentiating myelomonocytic leukemia 0.320578 Beran M 0.312167 World Health Organization 0.355665 neoplasias mielodisplásicas 0.314258 stem cell transplantation 0.313202 chronic myelogenous leukemia 0.364294 Germing U 0.362762 myeloproliferative disorders 0.313394 cases with chronic 0.311538 Leuk Lymphoma 0.332534	myelomonocytic leukemia from 0.33992 chronic myelomonocytic leukaemia 0.386185 juvenile chronic myelogenous 0.347073 marrow transplantation 0.341155 Organización Mundial 0.317633 chronic myeloid 0.357031 Differentiating juvenile myelomonocytic 0.319715 myeloid neoplasms 0.336696 bone marrow transplantation 0.325127 Bennett JM 0.319603 cromosoma filadelfia 0.337822 recuento plaquetario 0.325577 juvenile myelomonocytic leukaemia 0.339361 juvenile myelomonocytic leukemia 0.545157 chronic myeloid leukaemias 0.320258 Clin Oncol 0.32115 Orazi A 0.343564 Cooperative Leukaemia Group 0.311788 atypical chronic 0.319445 características clínicas 0.316309 trastornos mieloides 0.311632 leucemia mieloide aguda 0.316238 with chronic myelomonocytic 0.340508 Emanuel PD 0.350668	CLICK HERE
1946	National Cancer Institute	Html	es	Tratamiento del neuroblastoma (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del neuroblastoma.	glándula tiroides 0.633074 posibles efectos tardíos 0.641796 siguientes procedimientos 0.632822 células madre 0.931788 gen alk 0.612181 siguientes especialistas 0.624871 yodo 131-mibg 0.744725 vía oral 0.649411 rayos x 0.630232 enlace drugs approved 0.631928 estadios 2A 0.624814 niño ayuda 0.632627 ondas sonoras 0.629873 riesgo intermedio 0.674697 efectos tardíos 0.896983 cáncer.ampliar aspiración 0.633221	National Cancer Institute 0.612675 IRMN).Ampliar Imágenes 0.62564 siguientes tratamientos 0.624353 menor producción 0.628805 Instituto Nacional 0.623964 PDQ Tratamiento 0.634123 determinados cambios 0.611022 alta potencia 0.625499 presente sección 0.614217 nuevos tipos 0.61878 sistema nervioso central 0.655496 Physician Data Query 0.650241 siguientes pruebas 0.680017 siguientes estadios 0.629707 siguientes trastornos 0.624626	CLICK HERE
1953	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de los problemas de salud que continúan o aparecen después de terminar un tratamiento de cáncer.	válvulas cardíacas 0.300344 digestivasLos efectos tardíos 0.301994 siguientes procedimientos 0.300445 células madre 0.31868 suficiente saliva 0.300202 adultos jóvenes 0.300215 tumor tipo 0.3006 leucemia linfocítica aguda 0.300977 leucemia linfoblástica aguda 0.303718 diabetes mellitus 0.300401 rayos x 0.300187 largo plazo 0.301433 alta densidad 0.300367 debilidad súbitos 0.300398 efectos tardíos 0.995697 luz solar 0.30049 tumores benignos 0.300573	siguientes maneras 0.300324 hormonas tiroideas 0.300415 antecedentes familiares 0.302575 revestimiento protector 0.300332 hepatitis b 0.300262 siguientes factores 0.300516 radiación uv 0.300991 topoisomerasa ii 0.300497 suficiente insulina 0.300239 cuerpo elabora insulina 0.300315 Radiografía panorámica 0.300213 leucemia mieloide aguda 0.302575 mandíbulasLos problemas 0.300385 cáncer infantil meses 0.303991 biliaresLos efectos tardíos 0.30194 Mayor tiempo 0.300312 siguientes pruebas 0.300654	CLICK HERE
1986	National Cancer Institute	Html	es	Linfedema (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre la anatomía, la patofisiología, las manifestaciones clínicas, el diagnóstico y el tratamiento del linfedema relacionado con el cáncer, una afección en la que se acumula líquido linfático en los tejidos y causa inflamación..	after sentinel lymph 0.313822 Ridner SH 0.344357 group trial 0.315465 Sin embargo 0.344649 upper extremity lymphedema 0.331183 linfedema usa 0.380409 controlled trial with 0.318641 CA Cancer 0.317513 ganglios linfáticos centinelas 0.349529 arm lymphedema after 0.317881 extremity lymphedema after 0.335236 Cancer statistics 0.316994 treatment-related lymphedema 0.324253 lymphedema after breast 0.383555 ganglio centinela 0.352856 axillary sampling with 0.313496 conductos linfáticos subclavios 0.335825 Petrek JA 0.323456 Schmitz KH 0.339884 Sport Sci Rev 0.321461 controlled trial comparing 0.313482 randomized controlled 0.341872 Balancing lymphedema risk 0.334354 breast cancer-related lymphedema 0.386776 tronco linfático subclavio 0.332389	arm lymphedema 0.323652 axillary dissection with 0.315734 vena subclavia 0.3286 Care Cancer 0.334426 exercise versus deconditioning 0.326793 with axillary lymph 0.315505 ganglio linfático centinela 0.380935 with arm lymphedema 0.319809 Arch Phys Med 0.320628 discrepancia intramiembro 0.359416 Phys Med Rehabil 0.321125 breast carcinoma survivors 0.322235 lower-extremity lymphedema secondary 0.313534 with breast-cancer-related lymphedema 0.31752 Ahmed RL 0.322704 Clin Oncol 0.373772 breast cancer 0.91318 sentinel lymph 0.326667 Breast Cancer Study 0.332383 with or without 0.326647 Exerc Sport Sci 0.322466 axillary lymph 0.328084 Weight lifting 0.32136 Breast Cancer Res 0.331771	CLICK HERE
2022	National Cancer Institute	Html	es	Exámenes de detección del cáncer de cuello uterino (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre los exámenes que se utilizan para detectar el cáncer de cuello uterino.	siguientes grupos 0.30039 PDQ Exámenes 0.300773 Physician Data Query 0.301635 libre uso 0.300195 cuello uterino 0.99515 prevención revisa 0.300275 largo plazo 0.300411	principal factor 0.302387 información ayuda 0.300455 National Cancer Institute 0.300349 siguientes riesgos 0.300249 siguientes sumarios 0.301285 Instituto Nacional 0.300751	CLICK HERE
2064	National Cancer Institute	Html	es	Exposición al asbesto y el riesgo de cáncer	Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información.	técnicos profesionales automotrices 0.5421 gen bap1 0.530949 que familiares de trabajadores 0.533144 normas descritas 0.532666 largo plazo 0.526581 Protección Ambiental 0.672505 World Trade Center 0.546459 principal dependencia 0.532045 Ground Zero 0.529197 derrames pleurales benignos 0.558277 Salud Ocupacional 0.584399 asbesto crisótilo 0.987156 trabajadores portuarios 0.606054 Instituto Nacional 0.563708 menores riesgos 0.533274 Trabajo de EE 0.535904 Employment Standards Administration 0.548898 titulado current best practices 0.543841 Mine Safety 0.535362 sustancias tóxicas 0.635631 siglo xix 0.53032 distintos tipos 0.525229 Estados Unidos 0.992615 automotriz usa 0.531695 Public Affairs 0.529764	serios problemas 0.529441 Environmental Protection Agency 0.815767 línea telefónica tsca 0.556811 Preventing Asbestos Exposure 0.544747 Product Safety Commission 0.67091 Information Division 0.52746 Occupational Safety 0.586355 asbesto causa 0.952053 cuánto tiempo 0.527545 en la mucosidad 0.531534 a las personas 0.529484 posibles peligros 0.5266 Health Administration 0.652906 Consumer Product Safety 0.672282 causa dificultad 0.530297 sumamente bajo. Los fabricantes 0.528798 mejores prácticas 0.574094 Clutch Repair Workers 0.544379 Veterans Affairs 0.528386 Torres Gemelas 0.52642 Compensation Programs 0.5287 Disease Registry 0.526245 Toxic Substances 0.526971 Segunda Guerra Mundial 0.550565	CLICK HERE